

A pathway map of prolactin signaling

Aneesha Radhakrishnan · Rajesh Raju · Nirvana Tuladhar ·
Tejaswini Subbannayya · Joji Kurian Thomas · Renu Goel · Deepthi Telikicherla ·
Shyam Mohan Palapetta · B. Abdul Rahiman · Desai Dattatraya Venkatesh ·
Kulkarni-Kale Urmila · H. C. Harsha · Premendu Prakash Mathur ·
T. S. Keshava Prasad · Akhilesh Pandey · Carrie Shemanko · Aditi Chatterjee

Received: 28 February 2012 / Accepted: 24 May 2012 / Published online: 9 June 2012
© The International CCN Society 2012

Abbreviations

PRL	Prolactin	GH	Growth hormone
PRLR	Prolactin receptor	JAK2	Janus kinase 2
PL	Placental lactogen	STAT1	Signal transducer and activator of transcription 1 91 kDa

A. Radhakrishnan · R. Raju · T. Subbannayya · J. K. Thomas ·
R. Goel · D. Telikicherla · S. M. Palapetta · H. C. Harsha ·
T. S. K. Prasad · A. Chatterjee (✉)
Institute of Bioinformatics, International Tech Park,
Bangalore 560 066, India
e-mail: aditi@ibioinformatics.org

A. Radhakrishnan
e-mail: aneesha@ibioinformatics.org

R. Raju
e-mail: rajesh@ibioinformatics.org

T. Subbannayya
e-mail: tejaswini@ibioinformatics.org

J. K. Thomas
e-mail: joji@ibioinformatics.org

R. Goel
e-mail: renu@ibioinformatics.org

D. Telikicherla
e-mail: deepthi@ibioinformatics.org

S. M. Palapetta
e-mail: shyam@ibioinformatics.org

H. C. Harsha
e-mail: harsha@ibioinformatics.org

T. S. K. Prasad
e-mail: keshav@ibioinformatics.org

A. Radhakrishnan · P. P. Mathur
Department of Biochemistry and Molecular Biology,
Pondicherry University,
Puducherry 605014, India

P.P. Mathur
e-mail: pppmathur.bic@pondiuni.edu.in

R. Raju · R. Goel · D. Telikicherla · B. A. Rahiman
Department of Biotechnology, Kuvempu University,
Shankaraghatta 577 451, India

B. A. Rahiman
e-mail: rahimanbt@yahoo.com

N. Tuladhar · D. D. Venkatesh · K.-K. Urmila
Bioinformatics Centre, University of Pune,
Ganeshkhind Road,
Pune 411 007, India

N. Tuladhar
e-mail: nirvtul@gmail.com

D. Venkatesh
e-mail: datta@bioinfo.net.in

K.-K. Urmila
e-mail: urmila@bioinfo.net.in

T. Subbannayya · J. K. Thomas · T. S. K. Prasad
School of Biotechnology, Amrita Vishwa Vidyapeetham,
Kollam 690 525, India

S. M. Palapetta · P. P. Mathur · T. S. K. Prasad
Centre of Excellence in Bioinformatics, School of Life Sciences,
Pondicherry University,
Puducherry 605 014, India

T. S. K. Prasad
Manipal University,
Madhav Nagar,
Manipal, Karnataka 576 104, India

MAPK	Mitogen activated protein kinase
PI3-Kinase	Phosphoinositide 3-kinase
AKT1	v-akt murine thymoma viral oncogene homolog 1
RAC1	ras-related C3 botulinum toxin substrate 1
IRS1	Insulin receptor substrate 1
IRS2	Insulin receptor substrate 2
MTOR	Mammalian target of rapamycin
GSK3B	glycogen synthase kinase 3 beta
PAK1	p21 protein (Cdc42/Rac)-activated kinase 1
BioPAX	Biological Pathway eXchange
PSI-MI	Proteomics Standards Initiative for Molecular Interaction
SBML	Systems Biology Markup Language

Introduction

Prolactin (PRL) is a pleiotropic polypeptide hormone secreted primarily by the lactotrophic cells of anterior pituitary gland in vertebrates (Freeman et al. 2000). This hormone family includes placental lactogen (PL) and growth hormone (GH) (Corbacho et al. 2002). Prolactin plays a major role in lactation and reproduction and has been shown to have a multitude of effects relating to growth, development, metabolism, immunoregulation and protection (Ben-Jonathan et al. 2006). The prolactin signaling pathway is initiated by the binding of prolactin with the prolactin receptor (PRLR), a member of class I cytokine receptor superfamily (Binart et al. 2000), which is expressed in a variety of tissues. The PRLR comprises of an extracellular ligand binding domain, a transmembrane domain

and an intracellular domain. The PRLR lacks intrinsic kinase activity and transduces signal through kinases that interact with its cytoplasmic tail. Three constitutively active variants of the receptor have been reported in humans (Goffin et al. 2010). Though the signaling reactions downstream of the longest isoform of prolactin receptor have been well established, little is known about prolactin signaling initiated by six other isoforms (Bouilly et al. 2011). Studies also indicate that binding affinity of the human prolactin receptor to nonhuman prolactin is lower than human prolactin (Utama et al. 2009). The prolactin receptor also binds to hPL and hGH leading to the activation of downstream pathways. However, we have not considered these reactions in the current study. This study reports only those reactions, which occur upon stimulation of prolactin receptor with prolactin, based on the criteria described previously (Nanjappa et al. 2011).

Availability of signaling pathway information is useful to the biomedical research community, especially for systems biology approaches. Considering this, we have developed ‘NetPath’ as a resource of ligand-receptor specific signal transduction pathways (Kandasamy et al. 2010). As a part of this, we have carried out manual annotation of available information from the published literature for ligand-receptor signaling pathways (Raju et al. 2011a; Nanjappa et al. 2011; Telikicherla et al. 2011; Goel et al. 2012). Similarly, in this study, we enriched publicly available information pertaining to prolactin-prolactin receptor dependent signaling pathways and also generated a graphic map depicting the prolactin signaling pathway.

Materials and methods

A literature survey was carried out using PubMed for retrieving articles related to prolactin signaling using search terms ‘Prolactin’, ‘Prolactin Receptor’ and ‘Prolactin signaling’. We have categorized the molecular information into protein-protein interactions (PPIs), enzyme-substrate reactions (post-translational modifications), protein translocation events, activation/inhibition reactions and gene regulation. We have used PathBuilder, a software used for managing manually curated signaling data (Kandasamy et al. 2009). Information relevant to protein-protein interactions, enzyme-catalyzed reactions, subcellular translocation events, activation/inhibition reactions of proteins were captured from human and other mammalian cells/cell lines. Prolactin-induced transcriptional regulation of genes was also documented. In addition, we have also included information on transcriptional regulators downstream of prolactin signaling. For each category of events, along with the specific data, information has been provided for the source of protein, type of experiment and interaction location. The PubMed identifier of the research article, from which a particular reaction was annotated, has been provided as a hyperlink.

A. Pandey
McKusick-Nathans Institute of Genetic Medicine,
Johns Hopkins University School of Medicine,
Baltimore 21205, MD, USA
e-mail: pandey@jhmi.edu

A. Pandey
Department of Biological Chemistry,
Johns Hopkins University School of Medicine,
Baltimore 21205, MD, USA

A. Pandey
Department of Oncology,
Johns Hopkins University School of Medicine,
Baltimore 21205, MD, USA

A. Pandey
Department of Pathology,
Johns Hopkins University School of Medicine,
Baltimore 21205, MD, USA

C. Shemanko
Department of Biological Sciences, University of Calgary,
500 University Drive N.W.,
Calgary, AB, Canada T2N 1N4
e-mail: shemanko@ucalgary.ca

map can be accessed from NetSlim at http://www.netpath.org/netslim/NetSlim_56. The prolactin signaling map (map with citation) in NetSlim has citations for each reaction(s) linked to the reference articles in PubMed. Description of each protein involved in the signaling has been linked to its respective page in NetPath and to the molecule page of other resources such as HPRD (Goel et al. 2011). Genes which are downstream targets of the prolactin pathway are linked to their corresponding description under NCBI.

In humans, a 23 kDa full length prolactin and a 16 kDa N-terminal fragment of prolactin (16 K prolactin) have been reported. Full length prolactin has been reported to stimulate angiogenesis whereas 16 K PRL fragment has potent anti-angiogenic and vasoconstrictive activities (Struman et al. 1999). The 16 kDa prolactin fragment does not appear to bind to the PRLR (Corbacho et al. 2000) but is able to activate programmed cell death in the endothelial cells (Martini et al. 2000) (Fig. 1). The principal signaling pathway activated by prolactin-PRLR interaction is the JAK/STAT pathway. Prolactin binding induces the dimerization of the receptor and activation of JAK2, a kinase constitutively associated with PRLR (Pezet et al. 1997). JAK2 phosphorylates multiple tyrosine residues of PRLR and enables the binding of signal transducer and activator of transcription (STAT) proteins (DaSilva et al. 1996). Tyrosine-phosphorylated STAT5 dissociates from the receptor, dimerizes and translocates into the nucleus where it binds to the promoters of target genes. Even though JAK/STAT pathway is considered as one of the major downstream pathways for cytokine receptor signaling, prolactin also activates the MAP kinase pathway. Das et al., 1996 described the participation of RAS/RAF/MAPK cascade in prolactin mediated cell proliferation in mammary epithelial cells (Das and Vonderhaar 1996). Activation of the PI3-Kinase pathway upon prolactin exposure has been reported in multiple target cells. The pathway activation is dependent upon SRC family kinases in multiple cell types and it promotes survival of lymphoid cells (Dominguez-Caceres et al. 2004; Clevenger et al. 2003; Piazza et al. 2009). In response to prolactin, insulin receptor substrate 1 and 2 (IRS1 and IRS2) are phosphorylated in COS cells transfected with PRLR and have been shown to be associated with the regulatory subunit of PI3-kinase (Yamauchi et al. 1998). PI3-Kinase further activates AKT1 and leads to the activation of MTOR and its downstream targets (Bishop et al. 2006).

Prolactin also regulates cytoskeletal re-organization through the activation of the RAC pathway. The activation of Rho family of small GTP binding proteins such as RAC leads to the activation of p21 protein (Cdc42/Rac)-activated kinase 1 (PAK1) (Rider et al. 2007). These pathways and others, such as those involving tyrosine kinases Fyn, Tec, the guanine nucleotide exchange factor Vav, the phosphatase SHP-2, the signaling suppressors SOCS and CIS (Clevenger

et al. 2003), prolyl isomerase cyclophilin A (Clevenger et al. 2009) are presented in the NetPath web resource.

Prolactin signaling pathway information is compatible with multiple data exchange formats such as PSI-MI version 2.5 (Hermjakob et al. 2004), BioPAX level 3 (Demir et al. 2010) and SBML 2.1 (Hucka et al. 2003). The data for the prolactin signaling pathway is freely available for download in the formats mentioned above. The pathway diagram can be downloaded from NetSlim in .gpml, .pdf, and .png formats. We have also provided prolactin pathway information in Wikipathways (<http://www.wikipathways.org/index.php/Pathway:WP2037>).

Conclusions

Analysis of signaling events that occur upon interaction of specific ligand-receptor combinations are crucial for our understanding of biological processes that they regulate. We anticipate that the prolactin signaling map available through NetPath (http://www.netpath.org/pathways?path_id=NetPath_56) will facilitate further studies on prolactin associated signaling and related disorders. We will continue to update the prolactin pathway on a regular basis as more published literature becomes available.

Acknowledgments We thank the Department of Biotechnology (DBT), Government of India for research support to the Institute of Bioinformatics, Bangalore. Aneasha Radhakrishnan and Shyam Mohan Palapetta are recipients of Senior Research Fellowship from the Council of Scientific and Industrial Research (CSIR), New Delhi, India. Deepthi Telikicherla is a recipient of Senior Research Fellowship from Indian Council of Medical Research (ICMR), Government of India. P. P. Mathur thanks the Department of Biotechnology (DBT), Government of India and Department of Information Technology (DIT), Government of India for financial support (Project Nos.: BT/BI/03/015/2002 and DIT/R&D/BIO/15(9)/2007). Dattatraya V. Desai and Urmila Kulkarni-Kale gratefully acknowledge the facilities of the Bioinformatics Centre, University of Pune and the 'Centre of Excellence' grant by the Department of Biotechnology (DBT), Government of India as well as the Department of Information Technology (DIT), Government of India. H. C Harsha is a Wellcome Trust/DBT India Alliance Early Career Fellow. Dr. Carrie Shemanko is the "pathway authority" of this manuscript and has reviewed the molecular interactions.

References

- Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR (2006) Focus on prolactin as a metabolic hormone. *Trends Endocrinol Metab* 17:110–116
- Binar N, Ormandy CJ, Kelly PA (2000) Mammary gland development and the prolactin receptor. *Adv Exp Med Biol* 480:85–92
- Bishop JD, Nien WL, Dauphinee SM, Too CK (2006) Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells. *J Endocrinol* 190:307–312

- Bouilly J, Sonigo C, Auffret J, Gibori G, Binart N (2011) Prolactin signaling mechanisms in ovary. *Mol Cell Endocrinol*
- Clevenger CV, Furth PA, Hankinson SE, Schuler LA (2003) The role of prolactin in mammary carcinoma. *Endocr Rev* 24:1–27
- Clevenger CV, Gadd SL, Zheng J (2009) New mechanisms for PRLr action in breast cancer. *Trends Endocrinol Metab* 20:223–229
- Corbacho AM, Nava G, Eiserich JP, Noris G, Macotela Y, Struman I, Martinez De La Escalera G, Freeman BA, Clapp C (2000) Proteolytic cleavage confers nitric oxide synthase inducing activity upon prolactin. *J Biol Chem* 275:13183–13186
- Corbacho AM, Martinez De La Escalera G, Clapp C (2002) Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. *J Endocrinol* 173:219–238
- Das R, Vonderhaar BK (1996) Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells. *Oncogene* 13:1139–1145
- DaSilva L, Rui H, Erwin RA, Howard OM, Kirken RA, Malabarba MG, Hackett RH, Larner AC, Farrar WL (1996) Prolactin recruits STAT1, STAT3 and STAT5 independent of conserved receptor tyrosines TYR402, TYR479, TYR515 and TYR580. *Mol Cell Endocrinol* 117:131–140
- Demir E, Cary MP, Paley S, Fukuda K, Lemer C, Vastrik I, Wu G, D'Eustachio P, Schaefer C et al (2010) The BioPAX community standard for pathway data sharing. *Nat Biotechnol* 28:935–942
- Dominguez-Caceres MA, Garcia-Martinez JM, Calcabrini A, Gonzalez L, Porque PG, Leon J, Martin-Perez J (2004) Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells. *Oncogene* 23:7378–7390
- Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. *Physiol Rev* 80:1523–1631
- Goel R, Muthusamy B, Pandey A, Prasad TS (2011) Human protein reference database and human proteinpedia as discovery resources for molecular biotechnology. *Mol Biotechnol* 48:87–95
- Goel R, Raju R, Maharudraiah J, Kumar GSS, Ghosh K, Kumar A, Lashmi PT, Sharma J, Sharma R et al (2012) A signaling network of thyroid-stimulating hormone. *J Proteomics Bioinformatics*
- Goffin V, Bogorad RL, Touraine P (2010) Identification of gain-of-function variants of the human prolactin receptor. *Methods Enzymol* 484:329–355
- Hermjakob H, Montecchi-Palazzi L, Bader G, Wojcik J, Salwinski L, Ceol A, Moore S, Orchard S, Sarkans U et al (2004) The HUPO PSI's molecular interaction format—a community standard for the representation of protein interaction data. *Nat Biotechnol* 22:177–183
- Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, Arkin AP, Bornstein BJ, Bray D et al (2003) The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. *Bioinformatics* 19:524–531
- Kandasamy K, Keerthikumar S, Raju R, Keshava Prasad TS, Ramachandra YL, Mohan S, Pandey A (2009) PathBuilder—open source software for annotating and developing pathway resources. *Bioinformatics* 25:2860–2862
- Kandasamy K, Mohan SS, Raju R, Keerthikumar S, Kumar GS, Venugopal AK, Telikicherla D, Navarro JD, Mathivanan S et al (2010) NetPath: a public resource of curated signal transduction pathways. *Genome Biol* 11:R3
- Martini JF, Piot C, Humeau LM, Struman I, Martial JA, Weiner RI (2000) The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. *Mol Endocrinol* 14:1536–1549
- Nanjappa V, Raju R, Muthusamy B, Sharma J, Thomas JK, Nidhina PAH, Harsha HC, Pandey A, Anilkumar G et al (2011) A comprehensive curated reaction map of leptin signaling pathway. *J Proteomics Bioinformatics* 4:184–189
- Pezet A, Buteau H, Kelly PA, Edery M (1997) The last proline of Box 1 is essential for association with JAK2 and functional activation of the prolactin receptor. *Mol Cell Endocrinol* 129:199–208
- Piazza TM, Lu JC, Carver KC, Schuler LA (2009) SRC family kinases accelerate prolactin receptor internalization, modulating trafficking and signaling in breast cancer cells. *Mol Endocrinol* 23:202–212
- Raju R, Balakrishnan L, Nanjappa V, Bhattacharjee M, Getnet D, Muthusamy B, Kurian Thomas J, Sharma J, Rahiman BA et al. (2011a) A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway. *Database (Oxford)* 2011:bar021
- Raju R, Nanjappa V, Balakrishnan L, Radhakrishnan A, Thomas JK, Sharma J, Tian M, Palapetta SM, Subbannayya T et al (2011b) NetSlim: high-confidence curated signaling maps. *Database (Oxford)* 2011:bar032
- Rider L, Shatrova A, Feener EP, Webb L, Diakonova M (2007) JAK2 tyrosine kinase phosphorylates PAK1 and regulates PAK1 activity and functions. *J Biol Chem* 282:30985–30996
- Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, Weiner RI, Martial JA (1999) Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. *Proc Natl Acad Sci USA* 96:1246–1251
- Telikicherla D, Ambekar A, Palapetta SM, Dwivedi SB, Raju R, Sharma J, Prasad TS, Ramachandra YL, Mohan SS et al (2011) A comprehensive curated resource for Follicle Stimulating Hormone signaling. *BMC Res Notes* 4:408
- Utama FE, Tran TH, Ryder A, LeBaron MJ, Parlow AF, Rui H (2009) Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells. *Endocrinology* 150:1782–1790
- van Iersel MP, Kelder T, Pico AR, Hanspers K, Coort S, Conklin BR, Evelo C (2008) Presenting and exploring biological pathways with PathVisio. *BMC Bioinforma* 9:399
- Yamauchi T, Kaburagi Y, Ueki K, Tsuji Y, Stark GR, Kerr IM, Tsushima T, Akanuma Y, Komuro I et al (1998) Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3-kinase activation via JAK2 kinase. *J Biol Chem* 273:15719–15726